High pathological response rate in locally advanced esophageal cancer after neoadjuvant combined modality therapy: dose finding of a weekly chemotherapy schedule with protracted venous infusion of 5-fluorouracil and dose escalation of cisplatin, docetaxel and concurrent radiotherapy
Open Access
- 9 June 2005
- journal article
- research article
- Published by Elsevier BV in Annals of Oncology
- Vol. 16 (7), 1133-1139
- https://doi.org/10.1093/annonc/mdi207
Abstract
Background: This phase I study was aimed at defining the toxicity profile and pathological response rate of a neoadjuvant schedule including weekly docetaxel and cisplatin, protracted venous infusion (PVI) of 5-FU and concomitant radiotherapy (RT) in locally advanced esophageal cancer. Patients and methods: The schedule consisted of a first phase of chemotherapy alone and a second phase of concurrent chemoradiation. Initial doses were: docetaxel and cisplatin 20 mg/m2 on days 1, 8, 15, 29, 36 and 43 plus 5-FU 150 mg/m2 PVI on days 1–21 and 29–49; RT (40 Gy) started on day 29. In the following steps the doses were escalated up to docetaxel 35 mg/m2 and cisplatin 25 mg/m2 on days 1, 8, 15, 29, 36, 43, 50 and 57 plus 5-FU 180 mg/m2 PVI on days 1–21 and 150 mg/m2 PVI on days 29–63 concurrently with RT 50 Gy. Results: Forty-seven patients were enrolled and 46 completed the planned treatment. During the concomitant phase, grade 3–4 hematological toxicities occurred in three patients (6.5%) (or 3/174 cycles) and non-hematological toxicities in six patients (13%) (or 7/179 cycles). A pathological downstaging was obtained in 59.6% of the cases (28/47): complete remission (pCR) in 14 patients, near pCR (residual microfoci on the primary pN0) in eight patients, pT2 pN0 in three patients and partial response on the primary with positive lymph nodes in three patients. Six (13%) and 13 (28%) patients were considered stable and non-responders, respectively. In the last dose level, eight pCR and four near-pCR were obtained out of 15 patients. The maximum tolerable dose was not formally defined because dose escalation was stopped at the last dose level. Conclusion: This schedule represents a feasible treatment and the high pathological response rate is extremely encouraging; the doses found in the last dose-level are the basis for an ongoing phase II study at our institution.Keywords
This publication has 25 references indexed in Scilit:
- Preoperative chemoradiotherapy for oesophageal cancer: a systematic review and meta-analysisGut, 2004
- Comparison of old and new TNM systems for nodal staging in adenocarcinoma of the gastro-oesophageal junctionBritish Journal of Surgery, 2004
- Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal CancerAnnals of Surgery, 2003
- Concomitant weekly docetaxel, cisplatin and radiation therapy in locally advanced non-small cell lung cancer: a dose finding studyLung Cancer, 2003
- INT 0123 (Radiation Therapy Oncology Group 94-05) Phase III Trial of Combined-Modality Therapy for Esophageal Cancer: High-Dose Versus Standard-Dose Radiation TherapyJournal of Clinical Oncology, 2002
- Combination chemotherapy of the taxanes and antimetabolites: its use and limitationsEuropean Journal Of Cancer, 2001
- Preoperative (neoadjuvant) chemoradiotherapy in oesophageal cancerBritish Journal of Surgery, 2001
- Enhancement of radiation effects by combined docetaxel and carboplatin treatment in vitroRadiation Oncology Investigations, 1999
- Classification of adenocarcinoma of the oesophagogastric junctionBritish Journal of Surgery, 1998
- Docetaxel (Taxotere®) a review of preclinical and clinical experience. Part IAnti-Cancer Drugs, 1995